Business Description
Shanghai Henlius Biotech Inc
ISIN : CNE100003N76
Share Class Description:
HKSE:02696: Class HCompare
Compare
Traded in other countries / regions
02696.Hong Kong IPO Date
2019-09-25Description
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.16 | |||||
| Equity-to-Asset | 0.26 | |||||
| Debt-to-Equity | 1.57 | |||||
| Debt-to-EBITDA | 6.96 | |||||
| Interest Coverage | 7.49 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 0.45 | |||||
| Beneish M-Score | -2.19 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 102.1 | |||||
| 3-Year Book Growth Rate | -14.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 20.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 9.06 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 68.71 | |||||
| 9-Day RSI | 61.25 | |||||
| 14-Day RSI | 55.03 | |||||
| 6-1 Month Momentum % | 17.83 | |||||
| 12-1 Month Momentum % | 63.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.49 | |||||
| Quick Ratio | 0.33 | |||||
| Cash Ratio | 0.13 | |||||
| Days Inventory | 377.14 | |||||
| Days Sales Outstanding | 96.94 | |||||
| Days Payable | 265.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -1.78 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 73.96 | |||||
| Operating Margin % | 14.6 | |||||
| Net Margin % | 10.56 | |||||
| FCF Margin % | 1.27 | |||||
| ROE % | 14.03 | |||||
| ROA % | 3.13 | |||||
| ROIC % | 3.74 | |||||
| ROC (Joel Greenblatt) % | 14.68 | |||||
| ROCE % | 7.98 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 19.78 | |||||
| Forward PE Ratio | 14.48 | |||||
| PE Ratio without NRI | 18.76 | |||||
| Price-to-Owner-Earnings | 30.76 | |||||
| PS Ratio | 3.69 | |||||
| PB Ratio | 4.21 | |||||
| Price-to-Free-Cash-Flow | 294.53 | |||||
| Price-to-Operating-Cash-Flow | 10.19 | |||||
| EV-to-EBIT | 37 | |||||
| EV-to-Forward-EBIT | 19.35 | |||||
| EV-to-EBITDA | 24.41 | |||||
| EV-to-Forward-EBITDA | 12.15 | |||||
| EV-to-Revenue | 4.88 | |||||
| EV-to-Forward-Revenue | 2.51 | |||||
| EV-to-FCF | 366.39 | |||||
| Earnings Yield (Greenblatt) % | 2.7 | |||||
| FCF Yield % | 0.34 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shanghai Henlius Biotech Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 3,135.798 | ||
| EPS (TTM) (HK$) | 1.087 | ||
| Beta | 0.6 | ||
| Volatility % | 31.65 | ||
| 14-Day RSI | 55.03 | ||
| 14-Day ATR (HK$) | 0.474745 | ||
| 20-Day SMA (HK$) | 20.8275 | ||
| 12-1 Month Momentum % | 63.24 | ||
| 52-Week Range (HK$) | 11.2 - 23.45 | ||
| Shares Outstanding (Mil) | 543.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shanghai Henlius Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shanghai Henlius Biotech Inc Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shanghai Henlius Biotech Inc Frequently Asked Questions
What is Shanghai Henlius Biotech Inc(HKSE:02696)'s stock price today?
The current price of HKSE:02696 is HK$21.50. The 52 week high of HKSE:02696 is HK$23.45 and 52 week low is HK$11.20.
When is next earnings date of Shanghai Henlius Biotech Inc(HKSE:02696)?
The next earnings date of Shanghai Henlius Biotech Inc(HKSE:02696) is .
Does Shanghai Henlius Biotech Inc(HKSE:02696) pay dividends? If so, how much?
Shanghai Henlius Biotech Inc(HKSE:02696) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers